OrbiMed Advisors
Latest statistics and disclosures from Orbimed Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BSX, EWTX, LLY, Sinovac Biotech, ELVN, and represent 25.29% of Orbimed Advisors's stock portfolio.
- Added to shares of these 10 stocks: DHR (+$52M), UTHR (+$48M), CI (+$47M), ORIC (+$33M), ABVX (+$32M), ASND (+$31M), MLYS (+$27M), QURE (+$27M), EYPT (+$26M), APLS (+$24M).
- Started 23 new stock positions in MIST, VSTM, PASG, EYPT, DHR, QURE, TGTX, ATAI, ABT, MNMD. UTHR, Celcuity, ABVX, Imagenebio, PFE, BCRX, VTGN, CI, CELC, Carlsmed, SRRK, BTSG, STTK.
- Reduced shares in these 10 stocks: , , , Amr (-$48M), CYTK (-$36M), THRD (-$31M), LLY (-$28M), NTRA (-$26M), ARGX (-$26M), XENE (-$21M).
- Sold out of its positions in ABCL, AGIO, CPRX, Chemomab Therapeutics, CYTK, ENGN, IKNA, INMB, Iteos Therapeutics, Passage Bio. THC, THRD, TSBX, TYRA, UNH, VRTX, ZLAB, LSBCF.
- Orbimed Advisors was a net seller of stock by $-110M.
- Orbimed Advisors has $4.3B in assets under management (AUM), dropping by 7.15%.
- Central Index Key (CIK): 0001055951
Tip: Access up to 7 years of quarterly data
Positions held by OrbiMed Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Orbimed Advisors
Orbimed Advisors holds 104 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Boston Scientific Corporation (BSX) | 6.0 | $257M | -6% | 2.6M | 97.63 |
|
| Edgewise Therapeutics (EWTX) | 5.9 | $252M | 16M | 16.22 |
|
|
| Eli Lilly & Co. (LLY) | 5.4 | $230M | -10% | 301k | 763.00 |
|
| Sinovac Biotech SHS | 4.3 | $185M | 2.7M | 67.85 |
|
|
| Enliven Therapeutics (ELVN) | 3.8 | $163M | 8.0M | 20.47 |
|
|
| Alnylam Pharmaceuticals (ALNY) | 3.2 | $138M | -11% | 302k | 456.00 |
|
| Stryker Corporation (SYK) | 3.1 | $133M | 359k | 369.67 |
|
|
| Edwards Lifesciences (EW) | 3.1 | $131M | 1.7M | 77.77 |
|
|
| Intuitive Surgical Com New (ISRG) | 3.0 | $128M | 287k | 447.23 |
|
|
| Argenx Se Sponsored Adr (ARGX) | 3.0 | $127M | -17% | 172k | 737.56 |
|
| Sionna Therapeutics (SION) | 2.5 | $109M | 3.7M | 29.41 |
|
|
| Upstream Bio (UPB) | 2.5 | $107M | 5.7M | 18.81 |
|
|
| Disc Medicine (IRON) | 2.2 | $94M | 1.4M | 66.08 |
|
|
| Caris Life Sciences (CAI) | 2.1 | $92M | 3.0M | 30.25 |
|
|
| Silverback Therapeutics (SPRY) | 1.9 | $83M | 8.3M | 10.05 |
|
|
| Avidity Biosciences Ord (RNA) | 1.7 | $71M | -9% | 1.6M | 43.57 |
|
| Mbx Biosciences (MBX) | 1.6 | $70M | 4.0M | 17.50 |
|
|
| Cg Oncology (CGON) | 1.6 | $70M | -14% | 1.7M | 40.28 |
|
| Natera (NTRA) | 1.6 | $69M | -27% | 429k | 160.97 |
|
| Axsome Therapeutics (AXSM) | 1.5 | $65M | +24% | 532k | 121.45 |
|
| Apellis Pharmaceuticals (APLS) | 1.4 | $58M | +67% | 2.6M | 22.63 |
|
| Terns Pharmaceuticals (TERN) | 1.3 | $57M | 7.6M | 7.51 |
|
|
| Arrivent Biopharma (AVBP) | 1.3 | $56M | 3.0M | 18.45 |
|
|
| Mineralys Therapeutics (MLYS) | 1.3 | $56M | +93% | 1.5M | 37.92 |
|
| EXACT Sciences Corporation (EXAS) | 1.3 | $54M | +63% | 995k | 54.71 |
|
| Compass Therapeutics (CMPX) | 1.2 | $53M | 15M | 3.50 |
|
|
| Corvus Pharmaceuticals (CRVS) | 1.2 | $53M | 7.2M | 7.37 |
|
|
| Danaher Corporation (DHR) | 1.2 | $52M | NEW | 263k | 198.26 |
|
| Imagenebio Nonvoting | 1.2 | $51M | -48% | 6.2M | 8.15 |
|
| Crinetics Pharmaceuticals In (CRNX) | 1.2 | $50M | +4% | 1.2M | 41.65 |
|
| Neurocrine Biosciences (NBIX) | 1.2 | $50M | -19% | 354k | 140.38 |
|
| United Therapeutics Corporation (UTHR) | 1.1 | $48M | NEW | 115k | 419.21 |
|
| Cigna Corp (CI) | 1.1 | $47M | NEW | 163k | 288.25 |
|
| Oric Pharmaceuticals (ORIC) | 1.0 | $44M | +304% | 3.6M | 12.00 |
|
| Janux Therapeutics (JANX) | 1.0 | $43M | +45% | 1.8M | 24.44 |
|
| Roivant Sciences SHS (ROIV) | 1.0 | $41M | -2% | 2.7M | 15.13 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.9 | $38M | +457% | 192k | 198.81 |
|
| Si-bone (SIBN) | 0.9 | $38M | 2.6M | 14.72 |
|
|
| Scpharmaceuticals (SCPH) | 0.8 | $34M | 6.1M | 5.67 |
|
|
| Abivax Sa Sponsored Ads (ABVX) | 0.8 | $32M | NEW | 380k | 84.90 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.7 | $32M | -5% | 1.1M | 28.00 |
|
| Trevi Therapeutics (TRVI) | 0.7 | $30M | 3.3M | 9.15 |
|
|
| Integer Hldgs (ITGR) | 0.7 | $30M | -33% | 290k | 103.33 |
|
| Dyne Therapeutics (DYN) | 0.7 | $29M | +124% | 2.3M | 12.65 |
|
| Rapt Therapeutics Com New (RAPT) | 0.7 | $28M | -33% | 1.1M | 25.79 |
|
| Cytomx Therapeutics (CTMX) | 0.6 | $27M | 8.5M | 3.19 |
|
|
| Neuropace (NPCE) | 0.6 | $27M | 2.6M | 10.31 |
|
|
| Uniqure Nv SHS (QURE) | 0.6 | $27M | NEW | 459k | 58.37 |
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.6 | $26M | NEW | 1.8M | 14.24 |
|
| Akero Therapeutics (AKRO) | 0.6 | $25M | +149% | 526k | 47.48 |
|
| Adc Therapeutics Sa SHS (ADCT) | 0.6 | $24M | 5.9M | 4.00 |
|
|
| Thermo Fisher Scientific (TMO) | 0.5 | $23M | 47k | 485.02 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 0.5 | $22M | -13% | 215k | 100.99 |
|
| Abbott Laboratories Call Option (ABT) | 0.5 | $20M | NEW | 150k | 133.94 |
|
| Krystal Biotech (KRYS) | 0.4 | $18M | +1016% | 103k | 176.53 |
|
| Forte Biosciences Com New (FBRX) | 0.4 | $18M | 1.2M | 15.00 |
|
|
| Avalo Therapeutics Com New (AVTX) | 0.4 | $17M | +39% | 1.3M | 12.71 |
|
| Xenon Pharmaceuticals (XENE) | 0.4 | $17M | -55% | 420k | 40.15 |
|
| Carlsmed | 0.4 | $17M | NEW | 1.3M | 13.39 |
|
| Keros Therapeutics (KROS) | 0.4 | $16M | 1.0M | 15.82 |
|
|
| Prelude Therapeutics (PRLD) | 0.4 | $16M | 11M | 1.44 |
|
|
| Shattuck Labs (STTK) | 0.4 | $15M | NEW | 6.3M | 2.39 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 0.3 | $15M | 1.2M | 12.65 |
|
|
| Urogen Pharma (URGN) | 0.3 | $14M | +44% | 689k | 19.95 |
|
| Vir Biotechnology (VIR) | 0.3 | $14M | 2.4M | 5.71 |
|
|
| Amicus Therapeutics (FOLD) | 0.3 | $13M | -28% | 1.6M | 7.88 |
|
| Pfizer Call Option (PFE) | 0.3 | $13M | NEW | 500k | 25.48 |
|
| Brightspring Health Svcs (BTSG) | 0.3 | $12M | NEW | 414k | 29.56 |
|
| Tarsus Pharmaceuticals (TARS) | 0.3 | $12M | 198k | 59.43 |
|
|
| C4 Therapeutics Com Stk (CCCC) | 0.3 | $12M | -23% | 5.2M | 2.22 |
|
| Astrazeneca Sponsored Adr Call Option (AZN) | 0.3 | $12M | +50% | 150k | 76.72 |
|
| Cullinan Oncology (CGEM) | 0.3 | $11M | 1.9M | 5.93 |
|
|
| Vistagen Therapeutics Ord Call Option (VTGN) | 0.3 | $11M | NEW | 3.1M | 3.55 |
|
| Amylyx Pharmaceuticals (AMLX) | 0.2 | $10M | +139% | 751k | 13.59 |
|
| Adicet Bio (ACET) | 0.2 | $9.3M | 11M | 0.81 |
|
|
| Pmv Pharmaceuticals (PMVP) | 0.2 | $8.4M | -7% | 6.0M | 1.40 |
|
| Aadi Bioscience (WHWK) | 0.2 | $7.9M | 4.2M | 1.90 |
|
|
| Verastem Com New (VSTM) | 0.2 | $7.8M | NEW | 888k | 8.83 |
|
| Alumis (ALMS) | 0.2 | $7.7M | 1.9M | 3.99 |
|
|
| BioCryst Pharmaceuticals (BCRX) | 0.2 | $6.8M | NEW | 902k | 7.59 |
|
| Milestone Pharmaceuticals (MIST) | 0.2 | $6.4M | NEW | 3.2M | 2.00 |
|
| Repare Therapeutics Ord (RPTX) | 0.1 | $5.8M | 3.3M | 1.76 |
|
|
| Inspiremd (NSPR) | 0.1 | $5.1M | 2.1M | 2.41 |
|
|
| Bioage Labs (BIOA) | 0.1 | $4.7M | -14% | 791k | 5.88 |
|
| Jade Biosciences Com New (JBIO) | 0.1 | $4.6M | 531k | 8.63 |
|
|
| Q32 Bio (QTTB) | 0.1 | $4.5M | 2.3M | 1.98 |
|
|
| Mind Medicine Mindmed Com New (MNMD) | 0.1 | $4.3M | NEW | 368k | 11.79 |
|
| Celcuity (CELC) | 0.1 | $4.2M | NEW | 84k | 49.40 |
|
| Immatics SHS (IMTX) | 0.1 | $4.0M | -35% | 467k | 8.52 |
|
| Scholar Rock Hldg Corp Call Option (SRRK) | 0.1 | $3.7M | NEW | 100k | 37.24 |
|
| Tg Therapeutics Call Option (TGTX) | 0.1 | $3.6M | NEW | 100k | 36.12 |
|
| Imagenebio | 0.1 | $3.1M | NEW | 379k | 8.15 |
|
| Celcuity Note 2.750% 8/0 (Principal) | 0.1 | $2.7M | NEW | 2.0M | 1.34 |
|
| Insmed Com Par $.01 (INSM) | 0.0 | $1.9M | 14k | 144.01 |
|
|
| Atai Life Sciences Nv SHS (ATAI) | 0.0 | $1.8M | NEW | 347k | 5.29 |
|
| Korro Bio (KRRO) | 0.0 | $1.6M | 32k | 47.89 |
|
|
| Mural Oncology Pub Ord Shs (MURA) | 0.0 | $1.2M | 589k | 2.07 |
|
|
| Traws Pharma Com New (TRAW) | 0.0 | $1.1M | 606k | 1.85 |
|
|
| Alto Neuroscience Com Shs (ANRO) | 0.0 | $1.0M | 250k | 4.02 |
|
|
| Lyell Immunopharma Com New (LYEL) | 0.0 | $840k | 52k | 16.24 |
|
|
| Kezar Life Sciences Com New (KZR) | 0.0 | $752k | 193k | 3.90 |
|
|
| Xeris Pharmaceuticals (XERS) | 0.0 | $655k | 80k | 8.14 |
|
|
| Passage Bio Com New (PASG) | 0.0 | $474k | NEW | 59k | 8.03 |
|
| Dih Hldg Us Cl A (DHAI) | 0.0 | $358k | 1.9M | 0.19 |
|
Past Filings by Orbimed Advisors
SEC 13F filings are viewable for Orbimed Advisors going back to 2010
- Orbimed Advisors 2025 Q3 filed Nov. 14, 2025
- Orbimed Advisors 2025 Q2 filed Aug. 14, 2025
- Orbimed Advisors 2025 Q1 filed May 15, 2025
- Orbimed Advisors 2024 Q4 filed Feb. 14, 2025
- Orbimed Advisors 2024 Q3 filed Nov. 14, 2024
- Orbimed Advisors 2024 Q2 filed Aug. 14, 2024
- Orbimed Advisors 2024 Q1 filed May 15, 2024
- Orbimed Advisors 2023 Q4 filed Feb. 14, 2024
- Orbimed Advisors 2023 Q3 filed Nov. 14, 2023
- Orbimed Advisors 2023 Q2 filed Aug. 14, 2023
- Orbimed Advisors 2023 Q1 filed May 15, 2023
- Orbimed Advisors 2022 Q4 filed Feb. 14, 2023
- Orbimed Advisors 2022 Q3 filed Nov. 14, 2022
- Orbimed Advisors 2022 Q2 filed Aug. 15, 2022
- Orbimed Advisors 2022 Q1 filed May 16, 2022
- Orbimed Advisors 2021 Q4 filed Feb. 14, 2022